SinoMab BioScience Limited
HKEX:3681.HK
1.07 (HKD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 1.365 | 4.032 | 26.657 | 12.76 | 0 | 1.48 | 0 |
| Cost of Revenue
| 0.943 | 0 | 0 | 0 | 0 | 0 | 0.117 |
| Gross Profit
| 0.422 | 4.032 | 26.657 | 12.76 | 0 | 1.48 | -0.117 |
| Gross Profit Ratio
| 0.309 | 1 | 1 | 1 | 0 | 1 | 0 |
| Reseach & Development Expenses
| 135.409 | 180.368 | 199.113 | 103.402 | 214.342 | 47.283 | 32.603 |
| General & Administrative Expenses
| 97.441 | 82.427 | 131.935 | 71.085 | 61.544 | 2.014 | 0.991 |
| Selling & Marketing Expenses
| 0.174 | 0.164 | 1.465 | 0.925 | 0 | 0 | 0 |
| SG&A
| 97.615 | 82.591 | 133.4 | 72.01 | 61.544 | 2.014 | 0.991 |
| Other Expenses
| 0 | 0 | -0.18 | 0 | -0.077 | -0.617 | -0.016 |
| Operating Expenses
| 0.422 | 292.81 | 325.761 | 150.29 | 275.886 | 54.799 | 39.595 |
| Operating Income
| -229.575 | -258.927 | -305.856 | -162.652 | -273.944 | -54.799 | -39.595 |
| Operating Income Ratio
| -168.187 | -64.218 | -11.474 | -12.747 | 0 | -37.026 | 0 |
| Total Other Income Expenses Net
| -13.536 | -25.231 | 17.662 | 40.052 | -0.396 | -28.811 | -12.306 |
| Income Before Tax
| -243.111 | -284.158 | -288.194 | -122.6 | -276.282 | -83.61 | -51.901 |
| Income Before Tax Ratio
| -178.103 | -70.476 | -10.811 | -9.608 | 0 | -56.493 | 0 |
| Income Tax Expense
| 0 | 0 | 9.19 | 0 | 2.338 | -25.781 | -13.272 |
| Net Income
| -243.111 | -284.158 | -288.194 | -122.6 | -278.62 | -83.61 | -47.974 |
| Net Income Ratio
| -178.103 | -70.476 | -10.811 | -9.608 | 0 | -56.493 | 0 |
| EPS
| -0.24 | -0.29 | -0.29 | -0.12 | -0.33 | -0.083 | -0.048 |
| EPS Diluted
| -0.24 | -0.29 | -0.29 | -0.12 | -0.33 | -0.083 | -0.048 |
| EBITDA
| -200.463 | -244.293 | -296.429 | -158.61 | -273.65 | -80.449 | -38.492 |
| EBITDA Ratio
| -146.859 | -60.589 | -11.12 | -12.43 | 0 | -54.357 | 0 |